-
Targeting macrophage–fibroblast interactions in the failing heart Nat. Rev. Cardiol. (IF 41.7) Pub Date : 2024-12-16 Nikolaos G. Frangogiannis
-
Left atrial appendage closure after ablation: the best OPTION for patients with AF? Nat. Rev. Cardiol. (IF 41.7) Pub Date : 2024-12-11 Karina Huynh
Two studies presented at AHA 2024 Scientific Sessions describe the efficacy and safety of left atrial appendage closure after catheter ablation for atrial fibrillation and the 5-year outcomes of the largest randomized left atrial appendage closure trial to date comparing the safety and efficacy of two devices.
-
Pro-arrhythmic potential of proton-pump inhibitors Nat. Rev. Cardiol. (IF 41.7) Pub Date : 2024-12-09 Pietro Enea Lazzerini, Riccardo Accioli, Pier Leopoldo Capecchi, Maurizio Acampa
Population studies have reported that proton-pump inhibitors (PPIs) increase cardiovascular mortality, at least in part owing to an increased propensity for life-threatening arrhythmias, but these findings have largely been ignored. We propose a series of recommendations for prescribers of PPIs to ensure a balance of the benefits against the potential arrhythmic risks.
-
Unlocking excellence in health care: the power of inclusive and sensitive language in medicine Nat. Rev. Cardiol. (IF 41.7) Pub Date : 2024-11-20 Sarah M. Birkhoelzer, Sonia S. Anand
This call to action aims to increase awareness of inclusive language in medicine to enhance the experiences of patients and staff and improve health outcomes. Recognizing that terms change, we urge all health-care professionals to advocate for their colleagues and patients. This responsibility to educate the community should not fall exclusively onto marginalized communities.
-
Charting the future of cardiology with large language model artificial intelligence Nat. Rev. Cardiol. (IF 41.7) Pub Date : 2024-11-19 Ramsey M. Wehbe
-
Cholesterol crystals in the pathogenesis of atherosclerosis Nat. Rev. Cardiol. (IF 41.7) Pub Date : 2024-11-18 Yvonne Baumer, Jason Irei, William A. Boisvert
-
Trials and tribulations of cell therapy for heart failure: an update on ongoing trials Nat. Rev. Cardiol. (IF 41.7) Pub Date : 2024-11-15 Jianyi Jay Zhang, Steven M. Pogwizd, Keiichi Fukuda, Wolfram-Hubertus Zimmermann, Chengming Fan, Joshua M. Hare, Roberto Bolli, Philippe Menasché
-
Improving English proficiency for scientific communication by non-fluent speakers Nat. Rev. Cardiol. (IF 41.7) Pub Date : 2024-11-14 Dong Zhao, Maria Rubini
English has long been the dominant language in scientific communication. Although having a universal language for scientific communication is beneficial, this standard imposes a considerable barrier for researchers who do not speak English fluently. However, the current generation of scientists is overcoming this barrier through the use of artificial intelligence-based language tools.
-
Trade-offs between vessel-based and substrate-based nomenclatures for coronary heart diseases Nat. Rev. Cardiol. (IF 41.7) Pub Date : 2024-11-14 Robert A. Byrne, Adnan Kastrati
-
Monocytes migrate to the brain after MI to promote deep sleep to aid cardiac healing Nat. Rev. Cardiol. (IF 41.7) Pub Date : 2024-11-14 Irene Fernández-Ruiz
After myocardial infarction, monocytes are actively recruited to the brain to augment sleep power and abundance, which in turn helps to limit cardiac inflammation and promotes recovery.
-
Cardiodermatology: the heart of the connection between the skin and cardiovascular disease Nat. Rev. Cardiol. (IF 41.7) Pub Date : 2024-11-13 Joel M. Gelfand, William B. Song, Sinéad M. Langan, Michael S. Garshick
-
Our revered and mysterious heart Nat. Rev. Cardiol. (IF 41.7) Pub Date : 2024-11-06 Philip Kilner
A review of Robin Choudhury’s book The Beating Heart: The Art & Science of Our Most Vital Organ, which explores depictions and perceptions of the heart across millennia.
-
Nanomedicine-based strategies for the treatment of vein graft disease Nat. Rev. Cardiol. (IF 41.7) Pub Date : 2024-11-05 Zhuoming Zhou, Wei Chen, Yihai Cao, Reza Abdi, Wei Tao
-
Environmental sustainability in cardiovascular practice: current challenges and future directions Nat. Rev. Cardiol. (IF 41.7) Pub Date : 2024-10-25 Sanjay Rajagopalan, Scott McAlister, Jason Jay, Richard D. Pham, Robert D. Brook, Khurram Nasir, Mark. J. Nieuwenhuijsen, Philip Landrigan, Allegra Wiesler, Christina Vernon Sanborn, Justin R. Carron, Kara Hammond Brooks, Aruni Bhatnagar, Sadeer Al-Kindi
-
Translation of pathophysiological mechanisms of atrial fibrosis into new diagnostic and therapeutic approaches Nat. Rev. Cardiol. (IF 41.7) Pub Date : 2024-10-23 Ulrich Schotten, Andreas Goette, Sander Verheule
-
OpenEP and EP Workbench for electrophysiology data analysis Nat. Rev. Cardiol. (IF 41.7) Pub Date : 2024-10-23 Neil Bodagh, Steven E. Williams
In this Tools of the Trade article, Bodagh and Williams highlight the utility of OpenEP, an open-source platform that offers standardized solutions for storage and analysis of electroanatomic mapping data.
-
Lower your cholesterol early, and stick with it! Nat. Rev. Cardiol. (IF 41.7) Pub Date : 2024-10-18 Filip K. Swirski, Christoph J. Binder
-
Pathophysiology of dilated cardiomyopathy: from mechanisms to precision medicine Nat. Rev. Cardiol. (IF 41.7) Pub Date : 2024-10-11 Marta Gigli, Davide Stolfo, Marco Merlo, Gianfranco Sinagra, Matthew R. G. Taylor, Luisa Mestroni
-
Clinical and subclinical acute brain injury caused by invasive cardiovascular procedures Nat. Rev. Cardiol. (IF 41.7) Pub Date : 2024-10-11 Radosław Lenarczyk, Marco Proietti, Jan F. Scheitz, Dipen Shah, Eberhard Siebert, Diana A. Gorog, Jacek Kowalczyk, Nikolaos Bonaros, George Ntaios, Wolfram Doehner, Nicolas M. Van Mieghem, Sandor Nardai, Jan Kovac, Roland Fiszer, Roberto Lorusso, Eliano Navarese, Sergio Castrejón, Andrea Rubboli, José Miguel Rivera-Caravaca, Alaide Chieffo, Gregory Y. H. Lip
-
β-blockers after MI: does ABYSS confirm REDUCEd use after all? Nat. Rev. Cardiol. (IF 41.7) Pub Date : 2024-10-09 Robin Hofmann, Stefan James
In contrast to the ABYSS investigators’ interpretation of the primary results of their trial, we believe that β-blockers can be safely discontinued in the majority of patients after an uncomplicated myocardial infarction. However, in individuals developing symptoms of angina or heart failure, β-blocker treatment remains one of several guideline-recommended therapies.
-
The burden of atrial fibrillation in the Asia–Pacific region Nat. Rev. Cardiol. (IF 41.7) Pub Date : 2024-09-25 Christopher X. Wong, Hung Fat Tse, Eue-Kuen Choi, Tze-Fan Chao, Koichi Inoue, Katrina Poppe, Eugene Tan, Yoga Yuniadi, Erdie Fadreguilan, Sofian Johar, Ngai Yin Chan, Narayan Namboodiri, S. Mokaddas Hossain, Huang He, Thoranis Chantrarat, Abdul Raqib Bin Abd Ghani, Narantuya Davaakhuu, Nwe Nwe, Ghazala Irfan, Minh That Ton, Rohan Gunawardena, Prashanthan Sanders
-
Soil and water pollution and cardiovascular disease Nat. Rev. Cardiol. (IF 41.7) Pub Date : 2024-09-25 Thomas Münzel, Omar Hahad, Jos Lelieveld, Michael Aschner, Mark J. Nieuwenhuijsen, Philip J. Landrigan, Andreas Daiber
-
Turning back time: the promise of cardiac regeneration Nat. Rev. Cardiol. (IF 41.7) Pub Date : 2024-09-24 Elsa Lawrence, Catherine H. Wilson
Elsa Lawrence and Catherine Wilson discuss the study that reported the existence of a transient regenerative window in mammals.
-
Minority stress, discrimination and cardiovascular health Nat. Rev. Cardiol. (IF 41.7) Pub Date : 2024-09-24 John C. Lin, Dang Nguyen, Anthony Zhong
John C. Lin and colleagues explore the history of racial disparities in cardiovascular outcomes and discuss the landmark findings of the CARDIA study and its contribution to the minority stress model.
-
20 years of Nature Reviews Cardiology Nat. Rev. Cardiol. (IF 41.7) Pub Date : 2024-09-24
The 20th anniversary of Nature Reviews Cardiology comes at a time of exciting innovation for cardiovascular research and clinical cardiology, with the advent of nucleic acid-targeted therapeutics, applications of artificial intelligence, promotion of a healthy cardiovascular exposome, personalization of medicine, and recognition of the importance of diversity, equity and inclusion in health care.
-
Cryo-X-ray phase contrast imaging for 3D structural and molecular analysis of frozen biopsy samples Nat. Rev. Cardiol. (IF 41.7) Pub Date : 2024-09-23 Kan Yan Chloe Li, Anne Bonnin
In this Tools of the Trade article, Li and Bonnin describe the use of cryo-X-ray phase contrast imaging to assess frozen myocardial biopsy samples.
-
The molecular landscape of vascular cells in the human brain Nat. Rev. Cardiol. (IF 41.7) Pub Date : 2024-09-20 Elizabeth E. Crouch
-
Lysosomes in the immunometabolic reprogramming of immune cells in atherosclerosis Nat. Rev. Cardiol. (IF 41.7) Pub Date : 2024-09-20 Fabrizia Bonacina, Xiangyu Zhang, Nicolas Manel, Laurent Yvan-Charvet, Babak Razani, Giuseppe D. Norata
-
Benefit of vutrisiran in transthyretin amyloidosis with cardiomyopathy Nat. Rev. Cardiol. (IF 41.7) Pub Date : 2024-09-19 Gregory B. Lim
Data from the HELIOS-B trial show that RNA interference with vutrisiran reduces the risk of death and recurrent cardiovascular events in patients with transthyretin amyloidosis with cardiomyopathy.
-
TEER is non-inferior to surgery in patients with secondary mitral regurgitation Nat. Rev. Cardiol. (IF 41.7) Pub Date : 2024-09-19 Irene Fernández-Ruiz
In patients with heart failure and secondary mitral valve regurgitation, transcatheter edge-to-edge repair is non-inferior to mitral valve surgery with respect to a composite of death, hospitalization for heart failure, reintervention, implantation of an assist device or stroke at 1 year after the procedure, according to findings from the MATTERHORN trial.
-
Combining TAVI with PCI in patients with aortic stenosis and CAD Nat. Rev. Cardiol. (IF 41.7) Pub Date : 2024-09-19 Gregory B. Lim
In the NOTION-3 trial, percutaneous coronary intervention reduced the occurrence of major adverse cardiac events compared with conservative treatment in patients who were undergoing transcatheter aortic valve implantation for severe aortic stenosis and who had stable coronary artery disease.
-
Finerenone improves outcomes in HFmrEF and HFpEF Nat. Rev. Cardiol. (IF 41.7) Pub Date : 2024-09-19 Irene Fernández-Ruiz
The non-steroidal mineralocorticoid receptor antagonist finerenone reduces the risk of adverse outcomes in patients with heart failure with mildly reduced ejection fraction or with preserved ejection fraction, according to findings presented at the ESC Congress 2024.
-
Combined measure of inflammation, cholesterol and lipoprotein(a) predicts 30-year cardiovascular risk in women Nat. Rev. Cardiol. (IF 41.7) Pub Date : 2024-09-17 Karina Huynh
A single combined measurement of high-sensitivity C-reactive protein, LDL-cholesterol and lipoprotein(a) levels in plasma predicts incident cardiovascular events among women over a 30-year follow-up period, according to a new study.
-
Interferon response at the border zone of the infarcted heart Nat. Rev. Cardiol. (IF 41.7) Pub Date : 2024-09-17 Karina Huynh
Cardiomyocytes can activate the type I interferon response in the infarct border zone after myocardial infarction, indicating that the type I interferon pathway, in addition to its well-established role in antiviral responses, is also involved in cardiac injury.
-
Clonal haematopoiesis: an emerging causal risk factor for atherosclerotic CVD Nat. Rev. Cardiol. (IF 41.7) Pub Date : 2024-09-17 Jennifer Harman
New research suggests that the presence of clonal haematopoiesis is unidirectionally associated with the development of atherosclerosis and that colchicine holds potential therapeutic value.
-
The gut microbiota in thrombosis Nat. Rev. Cardiol. (IF 41.7) Pub Date : 2024-09-17 My Phung Khuu, Nadja Paeslack, Olga Dremova, Corinne Benakis, Klytaimnistra Kiouptsi, Christoph Reinhardt
-
Reproductive options and genetic testing for patients with an inherited cardiac disease Nat. Rev. Cardiol. (IF 41.7) Pub Date : 2024-09-17 Job A. J. Verdonschot, Aimee D. C. Paulussen, Neal K. Lakdawala, Christine E. M. de Die-Smulders, James S. Ware, Jodie Ingles
-
Differential roles of eosinophils in cardiovascular disease Nat. Rev. Cardiol. (IF 41.7) Pub Date : 2024-09-16 Junyan Xu, Junli Guo, Tianxiao Liu, Chongzhe Yang, Zhaojie Meng, Peter Libby, Jinying Zhang, Guo-Ping Shi
-
Atheroimmunology: keeping the immune system in atherosclerosis in check Nat. Rev. Cardiol. (IF 41.7) Pub Date : 2024-09-11 Claudia Monaco, Lea Dib
-
Pathophysiological insights into HFpEF from studies of human cardiac tissue Nat. Rev. Cardiol. (IF 41.7) Pub Date : 2024-08-28 Ahmed U. Fayyaz, Muhammad Eltony, Larry J. Prokop, Katlyn E. Koepp, Barry A. Borlaug, Surendra Dasari, Melanie C. Bois, Kenneth B. Margulies, Joesph J. Maleszewski, Ying Wang, Margaret M. Redfield
-
Stroke triggers an innate immune memory that drives cardiac dysfunction Nat. Rev. Cardiol. (IF 41.7) Pub Date : 2024-08-07 Irene Fernández-Ruiz
Acute ischaemic stroke induces persistent innate immune memory through epigenetic changes in myeloid progenitors in the bone marrow, and this innate immune training contributes to cardiac remodelling and dysfunction in the long term, according to a new study.
-
Mechanisms and treatment of pulmonary arterial hypertension Nat. Rev. Cardiol. (IF 41.7) Pub Date : 2024-08-07 Hossein-Ardeschir Ghofrani, Mardi Gomberg-Maitland, Lan Zhao, Friedrich Grimminger
-
Potential new therapeutic target for HFpEF Nat. Rev. Cardiol. (IF 41.7) Pub Date : 2024-07-29 Irene Fernández-Ruiz
A new small-molecule inhibitor of vasohibins reduces myocardial stiffness and improves diastolic relaxation in a rat model of HFpEF.
-
Epidemiology of cardiometabolic health in Latin America and strategies to address disparities Nat. Rev. Cardiol. (IF 41.7) Pub Date : 2024-07-25 Luisa C. C. Brant, J. Jaime Miranda, Rodrigo M. Carrillo-Larco, David Flood, Vilma Irazola, Antonio Luiz P. Ribeiro
-
Reactive oxygen species in hypertension Nat. Rev. Cardiol. (IF 41.7) Pub Date : 2024-07-24 Livia L. Camargo, Francisco J. Rios, Augusto C. Montezano, Rhian M. Touyz
-
Cardiac sarcomere turnover by unidirectional replacement of proteins Nat. Rev. Cardiol. (IF 41.7) Pub Date : 2024-07-22 Gregory B. Lim
A new study indicates that proteins in the sarcomere complex are stochastically removed and degraded and are replaced by newly translated proteins. Sarcomere turnover occurs at a similar rate within cardiomyocytes and across the heart and slows with ageing.
-
Standardization and clinical applications of retinal imaging biomarkers for cardiovascular disease: a Roadmap from an NHLBI workshop Nat. Rev. Cardiol. (IF 41.7) Pub Date : 2024-07-22 Emily Y. Chew, Stephen A. Burns, Alison G. Abraham, Mathieu F. Bakhoum, Joshua A. Beckman, Toco Y. P. Chui, Robert P. Finger, Alejandro F. Frangi, Rebecca F. Gottesman, Maria B. Grant, Henner Hanssen, Cecilia S. Lee, Michelle L. Meyer, Damiano Rizzoni, Alicja R. Rudnicka, Joel S. Schuman, Sara B. Seidelmann, W. H. Wilson Tang, Bishow B. Adhikari, Narasimhan Danthi, Yuling Hong, Diane Reid, Grace L
-
Functional control of myosin motors in the cardiac cycle Nat. Rev. Cardiol. (IF 41.7) Pub Date : 2024-07-19 Malcolm Irving
-
Computational modelling of cardiovascular pathophysiology to risk stratify commercial spaceflight Nat. Rev. Cardiol. (IF 41.7) Pub Date : 2024-07-19 Paul D. Morris, Ryan A. Anderton, Karina Marshall-Goebel, Joseph K. Britton, Stuart M. C. Lee, Nicolas P. Smith, Frans N. van de Vosse, Karen M. Ong, Tom A. Newman, Daniel J. Taylor, Tim Chico, Julian P. Gunn, Andrew J. Narracott, D. Rod Hose, Ian Halliday
-
Dietary patterns to promote cardiometabolic health Nat. Rev. Cardiol. (IF 41.7) Pub Date : 2024-07-17 Neha J. Pagidipati, Pam R. Taub, Robert J. Ostfeld, Carol F. Kirkpatrick
-
Cardiac involvement in Chagas disease and African trypanosomiasis Nat. Rev. Cardiol. (IF 41.7) Pub Date : 2024-07-15 Ester Cerdeira Sabino, Maria Carmo P. Nunes, Johannes Blum, Israel Molina, Antonio Luiz P. Ribeiro
-
Consequences of ionizing radiation exposure to the cardiovascular system Nat. Rev. Cardiol. (IF 41.7) Pub Date : 2024-07-10 James W. S. Jahng, Mark P. Little, Hyunsoo J. No, Billy W. Loo, Joseph C. Wu
-
The LDL cumulative exposure hypothesis: evidence and practical applications Nat. Rev. Cardiol. (IF 41.7) Pub Date : 2024-07-05 Brian A. Ference, Eugene Braunwald, Alberico L. Catapano
-
Transcatheter treatment of pure aortic regurgitation Nat. Rev. Cardiol. (IF 41.7) Pub Date : 2024-06-27 Marco Barbanti, Giulia Laterra, Francesco Maisano
-
Autoimmune diseases and atherosclerotic cardiovascular disease Nat. Rev. Cardiol. (IF 41.7) Pub Date : 2024-06-27 Florentina Porsch, Christoph J. Binder
-
Global epidemiology of heart failure Nat. Rev. Cardiol. (IF 41.7) Pub Date : 2024-06-26 Muhammad Shahzeb Khan, Izza Shahid, Ahmed Bennis, Amina Rakisheva, Marco Metra, Javed Butler
-
Pulsed-field ablation: a revolution in atrial fibrillation therapy Nat. Rev. Cardiol. (IF 41.7) Pub Date : 2024-06-25 Leonid Maizels, Jonathan M. Kalman
The advent of pulsed-field ablation — a series of ultra-rapid, high-energy pulses that result in non-thermal cell death via electroporation — is revolutionizing the field of atrial fibrillation ablation. Data on first iterations of the technology indicate that safety and efficacy are at least similar to that of thermal ablation but with meaningfully shorter procedure duration.
-
Proximity-based labelling for proteomic mapping Nat. Rev. Cardiol. (IF 41.7) Pub Date : 2024-06-19 Zuzanna Jablonska
In this Tools of the Trade article, Jablonska describes the use of proximity-based labelling for the proteomic profiling of novel protein–protein interactions.
-
Suture-to-scan: ultrasonography-guided induction of heart injury Nat. Rev. Cardiol. (IF 41.7) Pub Date : 2024-06-19 Bronwyn Berkeley, Adrian Thomson
In this Tools of the Trade article, Berkeley and Thomson describe the use of a minimally invasive strategy to standardize the induction of myocardial infarction in mice.
-
Epigenetic changes in HSCs contribute to HF and comorbidities Nat. Rev. Cardiol. (IF 41.7) Pub Date : 2024-06-12 Karina Huynh
Findings from a new study published in Science Immunology suggest that epigenetic changes in haematopoietic stem cells promote the production of pro-inflammatory macrophages and influence their capacity to generate protective macrophage subsets.